Janusq, LLC
Publicly observedRocky River, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Rocky River | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Janusq, LLC | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | DKRHA61KMNX4 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant22 Sept 2025Publicly observed
NIH SBIR/STTR award: Pharmacokinetics and in vivo efficacy of DA1 macrocyclic peptides in a murine model of Alzheimer's disease
USD 576,664.00 · National Institute on Aging · Source: NIH RePORTER (opens in a new tab)
- Grant15 Sept 2025Publicly observed
NIH SBIR/STTR award: In vivo efficacy and in vitro toxicity assessment of peptide-based therapy HV-3 for the Treatment of Huntington's disease
USD 207,510.00 · National Institute of Neurological Disorders and Stroke · Source: NIH RePORTER (opens in a new tab)
- Grant15 Sept 2025Publicly observed
NIH SBIR/STTR award: In vivo efficacy and in vitro toxicity assessment of peptide-based therapy HV-3 for the Treatment of Huntington's disease
USD 490,501.00 · National Institute of Neurological Disorders and Stroke · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.